Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHemogenyx Pharmaceuticals Regulatory News (HEMO)

Share Price Information for Hemogenyx Pharmaceuticals (HEMO)

Share Price is delayed by 15 minutes
Get Live Data
739.00    -31.00 (-4.03%)
Bid:
741.00
Ask:
809.00
Spread: 68.00 (9.177%)
Market Cap: £50.25m
HEMO Live PriceLast checked at - London Stock Exchange

Intraday Hemogenyx Pharmaceuticals Share Chart

Director/PDMR Shareholding

12 Feb 2018 07:00

RNS Number : 5133E
Hemogenyx Pharmaceuticals PLC
12 February 2018
 

Hemogenyx Pharmaceuticals Plc 

("Hemogenyx" or the "Company")

 

Director / PDMR Shareholding

 

Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow and blood stem cell transplantation, announces that it has been advised that on 9 February 2018 Adrian Beeston, Non-Executive Director, purchased 200,000 ordinary shares of £0.01 each in the Company ("Ordinary Shares") at a price of 2.1p per share. Following this transaction Mr Beeston now has an interest in 6,331,969 Ordinary Shares, representing approximately 1.78 per cent. of the Company's issued share capital.

 

The Notification of Dealing Form provided in accordance with the requirements of MAR in relation to the transactions listed above are set out below:

 

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Adrian Beeston

 

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Non-executive Director

 

b)

 

Initial notification /Amendment

 

 

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

Hemogenyx Pharmaceuticals Plc

b)

 

LEI

 

 

n/a

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of £0.01 each

Identification code

ISIN GB00BYX3WZ24

 

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

 

 

Price(s)

Volume(s)

 

 

2.1p

200,000

 

 

 

 

 

d)

 

Aggregated information

- Aggregated volume

 N/A - single transaction

- Price

e)

 

Date of the transaction

 

 

9 February 2018

f)

 

Place of the transaction

 

 

London Stock Exchange

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
DSHBIGDDDDGBGIC
Date   Source Headline
24th Mar 20257:00 amRNSFirst Patient Safety
17th Mar 20257:00 amRNSRecruitment of Second Patient for Clinical Trials
13th Mar 20253:10 pmRNSConversion of convertible loan notes
11th Mar 20257:00 amRNSInstitutional investment
24th Feb 20257:00 amRNSFirst-in-Human Treatment with HG-CT-1
19th Feb 20254:50 pmRNSIssue of convertible loan notes
31st Jan 20259:35 amRNSTotal Voting Rights
8th Jan 20257:00 amRNSPlacing to raise £340,000
2nd Jan 20257:00 amRNSChange of Company Secretary and Registered Office
31st Dec 20247:00 amRNSTotal Voting Rights
30th Dec 20247:00 amRNSOpening of First Clinical Site
19th Dec 20247:00 amRNSUltrafast CAR-T Manufacturing
10th Dec 20244:10 pmRNSAdmission of New Ordinary Shares and New ISIN
9th Dec 20241:30 pmRNSResult of Extraordinary General Meeting
9th Dec 20247:00 amRNSSite Initiation Visit Completed
6th Dec 20247:00 amRNSCBR Macrophage Delivery Update
29th Nov 20247:00 amRNSTotal Voting Rights
22nd Nov 202412:49 pmRNSNotice of Extraordinary General Meeting
22nd Nov 20247:00 amRNSIRB Approval for Phase I Clinical Trial
11th Nov 20247:00 amRNSInstitutional Investment
30th Oct 20247:00 amRNSSchedule for Phase I Clinical Trial Opening
2nd Oct 202411:19 amRNSStrategic Investment from Prevail Partners, LLC
27th Sep 20247:00 amRNSHalf-year Report
9th Sep 20247:00 amRNSFLT3 Assay Ready for Phase I Trials at MD Anderson
2nd Sep 20247:00 amRNSCDX Development Update
28th Aug 20247:00 amRNSPresentation at CBD S&T Conference
27th Jun 20244:39 pmRNSResult of Annual General Meeting
17th Jun 20247:00 amRNSOperations Update
3rd Jun 20247:00 amRNSPosting of Annual Report & Notice of AGM
25th Apr 20247:00 amRNSFinal Results
28th Mar 20247:00 amRNSTotal Voting Rights
29th Feb 20247:00 amRNSPlacing to Raise US$4.2 million
16th Feb 20247:00 amRNSCBR Brain Delivery
14th Feb 20247:00 amRNSCBR Intranasal Delivery
9th Feb 20247:00 amRNSFDA Consents to Phase I Trials of HEMO-CAR-T
2nd Feb 20247:00 amRNSApproval and Issuance of U.S. Conditioning Patent
16th Jan 20247:00 amRNSSubmission of Complete Response to Clinical Hold
8th Jan 20247:00 amRNSHEMO-CAR-T Process Qualification Run Completed
28th Nov 202312:19 pmRNSPlacing to Raise £534,375
27th Nov 20237:00 amRNSCBR Expanded to Treatment of Cancer
15th Nov 20237:00 amRNSLentivirus Re-manufacturing Completed
31st Oct 20237:00 amRNSTotal Voting Rights
28th Sep 202312:28 pmRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic Investment from Prevail Partners, LLC
14th Sep 20237:00 amRNSClinical Hold Lift Plan is accepted by FDA
8th Sep 20235:11 pmRNSCBR Patent Application Update
10th Jul 20237:00 amRNSFull FDA Review for HEMO-CAR-T IND
30th Jun 20234:07 pmRNSResult of Annual General Meeting
2nd Jun 20232:01 pmRNSPosting of Annual Report & Notice of AGM
2nd Jun 202311:24 amRNSClinical Hold on IND for HEMO-CAR-T

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.